Catalog No.
DHD10802
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
Concentration
1.31 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15391
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CD19, MEDI-551, CAS: 1299440-37-1
Clone ID
Inebilizumab
Inebilizumab: First Approval, PMID: 32729016
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial, PMID: 31495497
Inebilizumab-cdon, PMID: 32936251
Antibodies to watch in 2020, PMID: 31847708
Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder, PMID: 33223088
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies, PMID: 27886126
New therapies for neuromyelitis optica spectrum disorder, PMID: 33186537
Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder, PMID: 34061127
Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2, PMID: 33411674
Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder, PMID: 33011853
Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1, PMID: 33406479
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects, PMID: 33059216
Update on neuromyelitis optica spectrum disorder, PMID: 33009077
Immunotherapy in myasthenia gravis in the era of biologics, PMID: 30573759
Emerging drugs for the treatment of neuromyelitis optica, PMID: 32731771
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52), PMID: 29447988
Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody, PMID: 30575890
A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma, PMID: 30915717
Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases, PMID: 32304439
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study, PMID: 29143550
Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS, PMID: 33372052
Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder), PMID: 34011260
Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease, PMID: 29956883
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder, PMID: 33771837
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD, PMID: 33538237
Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders, PMID: 33301078
Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders, PMID: 32228250
B cells in multiple sclerosis therapy-A comprehensive review, PMID: 29512131
Immune reconstitution therapy in NMOSD, PMID: 33992916
Lupus and NMOSD: The Blending of Humoral Autoimmunity, PMID: 33123402
Satralizumab in the treatment of neuromyelitis optica spectrum disorder, PMID: 33167776
Efficiency of antibody therapy in demyelinating diseases, PMID: 28910968
Investigational drugs in development to prevent neuromyelitis optica relapses, PMID: 29465257
Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder, PMID: 32865549
Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials, PMID: 32442886
New Therapeutic Landscape in Neuromyelitis Optica, PMID: 33814893
Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients, PMID: 31657826
B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders, PMID: 33419217
[Neuromyelitis Optica Spectrum Disorder], PMID: 34006678
Recent advances in the treatment of neuromyelitis optica spectrum disorders, PMID: 33741809
Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders, PMID: 32777005
Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka, PMID: 31387865
Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New?, PMID: 33777853
Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics, PMID: 33909234
Rituximab for the Treatment of Neuromyelitis Optica Spectrum Disorder [Internet], PMID: 34165925
Clinical Utility of Antiretinal Antibody Testing, PMID: 33885761
Clinical spectrum of high-titre GAD65 antibodies, PMID: 33563803
A lifetime aging study of human CD19 transgenic mice, PMID: 28243835
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker, PMID: 33724534
The frequency of longitudinally extensive transverse myelitis in MS: A population-based study, PMID: 31707235
For research use only. Not for human or drug use.
